Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 7/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 5/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2610424 | 0.77 | HCRTR2 (0.46) | HCRTR2HCRTR1 | |
| SCHEMBL2610423 | 0.76 | HCRTR2 (0.45) | HCRTR2HCRTR1 | |
| SCHEMBL2117104 | 0.75 | HCRTR2 (0.39) | MAOBHCRTR2HCRTR1SLC6A2SLC6A4 | |
| SCHEMBL15177909 | 0.75 | HCRTR2 (0.37) | MAOBHCRTR2HCRTR1SLC6A2SLC6A4 | |
| SCHEMBL9950661 | 0.73 | HCRTR2 (0.64) | HCRTR2HCRTR1 | |
| SCHEMBL10188722 | 0.70 | HCRTR2 (0.56) | HCRTR2HCRTR1KCNH2LMNA | |
| SCHEMBL2118887 | 0.70 | HCRTR1 (0.57) | HCRTR2HCRTR1KCNH2 | |
| SCHEMBL9950968 | 0.69 | HCRTR2 (0.41) | HCRTR2HCRTR1KCNH2 | |
| SCHEMBL4025554 | 0.69 | SLC6A2 (0.39) | MAOBSLC6A2SLC6A4 | |
| SCHEMBL4024571 | 0.69 | SLC6A2 (0.39) | MAOBSLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2626350-B1 | CYCLOPROPANE COMPOUND | EISAI R&D MAN CO LTD (JP) | 2015-04-15 | — | — | EP | disclosed |
| US-8268848-B2 | Cyclopropane compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-20120095031-A1 | CYCLOPROPANE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095031-A1 | CYCLOPROPANE COMPOUND | HCRTR1, HCRTR2, CNR1 | MAOB 344/4885HCRTR2 2/4885HCRTR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.